Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient

Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento

Research output: Contribution to journalArticle

2 Citations (Scopus)

Fingerprint Dive into the research topics of 'Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient'. Together they form a unique fingerprint.

Medicine & Life Sciences